The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALXO | +11.49% | -96.13% | -47.83% | -95% |
| S&P | +14.84% | +96.04% | +14.41% | +109% |
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.19M | 13.2% |
| Market Cap | $22.18M | -92.9% |
| Market Cap / Employee | $0.28M | 0.0% |
| Employees | 80 | 11.1% |
| Net Income | -$25.95M | 34.1% |
| EBITDA | -$23.28M | 43.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $19.30M | 24.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.13M | -29.2% |
| Short Term Debt | $5.05M | 189.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -75.22% | -0.8% |
| Return On Invested Capital | -52.28% | 53.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.45M | 12.0% |
| Operating Free Cash Flow | -$23.41M | 11.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.60 | 0.64 | 0.29 | 0.25 | -86.41% |
| Price to Tangible Book Value | 0.60 | 0.64 | 0.29 | 0.25 | -86.41% |
| Enterprise Value to EBITDA | 1.09 | 0.74 | 1.52 | 1.76 | -141.92% |
| Return on Equity | -98.9% | -88.9% | -103.0% | -104.2% | 13.06% |
| Total Debt | $17.36M | $16.98M | $16.59M | $16.18M | -7.38% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
